Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

The potential move to rescind authorization of Pfizer's vaccine could leave some kids in the U.S. with no available shots ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

Pfizer (PFE 0.06%) has been a terrible investment over the past three years. Revenue and earnings have generally moved in the wrong direction, as the company has been unable to fo ...

Pfizer has launched its 20-valent pneumococcal conjugate vaccine (PCV20) in India, offering single-dose protection against 20 ...

Pfizer said its antibody-drug conjugate Padcev extended survival when combined with the immunotherapy Keytruda in some ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Pfizer launches PCV20 for adults in India to offer broad protection against pneumococcal disease: Our Bureau, Mumbai Wednesday, August 13, 2025, 15:45 Hrs [IST] Pfizer has announc ...

Those who invested in Pfizer three years ago and hung on are not thrilled. They would have done much better with a simple S&P ...